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a public-private collaboration aiming to develop and test a system for rapid benefit-risk (B/R) monitoring
of vaccines using European healthcare databases. Event misclassification can result in biased estimates.
Using different algorithms for identifying cases of Bordetella pertussis (BorPer) infection as a test case, we
aimed to describe a strategy to quantify event misclassification, when manual chart review is not feasible.
Methods: Four participating databases retrieved data from primary care (PC) setting: BIFAP: (Spain), THIN
and RCGP RSC (UK) and PEDIANET (Italy); SIDIAP (Spain) retrieved data from both PC and hospital set-
tings. BorPer algorithms were defined by healthcare setting, data domain (diagnoses, drugs, or laboratory
tests) and concept sets (specific or unspecified pertussis). Algorithm- and database-specific BorPer inci-
dence rates (IRs) were estimated in children aged 0–14 years enrolled in 2012 and 2014 and followed up
until the end of each calendar year and compared with IRs of confirmed pertussis from the ECDC surveil-
lance system (TESSy). Novel formulas were used to approximate validity indices, based on a small set of
assumptions. They were applied to approximately estimate positive predictive value (PPV) and sensitivity
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in the ADVANCE project, Vaccine, https://doi.orResults: The number of cases and the estimated BorPer IRs per 100,000 person-years in PC, using data
representing 3,173,268 person-years, were 0 (IR = 0.0), 21 (IR = 4.3), 21 (IR = 5.1), 79 (IR = 5.7), and 2
(IR = 2.3) in BIFAP, SIDIAP, THIN, RCGP RSC and PEDIANET respectively. The IRs for combined specific/
unspecified pertussis were higher than TESSy, suggesting that some false positives had been included.
In SIDIAP the estimated IR was 45.0 when discharge diagnoses were included. The sensitivity and PPV
of combined PC specific and unspecific diagnoses for BorPer cases in SIDIAP were approximately 85%
and 72%, respectively.
Conclusion: Retrieving BorPer cases using only specific concepts has low sensitivity in PC databases,
while including cases retrieved by unspecified concepts introduces false positives, which were approxi-
mately estimated to be 28% in one database. The share of cases that cannot be retrieved from a PC data-
base because they are only seen in hospital was approximately estimated to be 15% in one database. This
study demonstrated that quantifying the impact of different event-finding algorithms across databases
and benchmarking with disease surveillance data can provide approximate estimates of algorithm
validity.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
ADVANCE is a public-private collaboration aiming to develop
and test a system for rapid benefit-risk (B/R) monitoring of vacci-
nes using existing healthcare databases in Europe [1] (see Appen-
dix for list of consortium members). These databases have proven
very useful for studying drug effects and are commonly used in
pharmacoepidemiology [2].
Identifying events, such as vaccine-preventable diseases,
adverse events of interest, co-morbidities and exposure to vaccina-
tion, is a pivotal first step in vaccine B/R studies. Since there is lim-
ited or no control over the primary data collection when using
existing healthcare databases, event retrieval is usually not perfect.
Individuals who experienced the event might not be retrieved, for
example if an individual is admitted to hospital for the event but
no primary care (PC) diagnosis is recorded, the event will not be
retrieved from PC databases: those individuals will be false nega-
tives. Conversely, some individuals might be identified as having
the event when in fact they did not: those individuals will be false
positives. In a PC database, this typically happens when the physi-
cian had only a suspicion, or if it was a ruled-out diagnosis, or if a
prevalent condition was recorded in a way that may be retrieved as
a new diagnosis, or if a diagnosis was miscoded, or if the diagnosis
was incorrect.
It is well established that misclassification of events (false pos-
itives or false negatives) can introduce bias in epidemiological
studies, which can be corrected, to some extent, using statistical
methods [5–7]. However, to correct this bias, some validity param-
eters such as sensitivity and positive predictive value (PPV) are
required [8]. For this a gold standard, such as chart reviews, is
required, which generally makes it costly and time-consuming.
Researchers who access these databases usually develop their
own methods to identify events of interest, which are not always
fully transparent [3,4]. Events may be retrieved by combining
information from different settings (e.g., PC and hospital) and data
domains, for example diagnostic codes, drugs as proxies (e.g. in the
case of diabetes), or laboratory measurements. Use of information
from more than one data domain, compared with using diagnoses
information only, or from more than one setting, such as PC and
hospital versus PC alone, can alter the sensitivity and PPV of the
event-finding algorithm: indeed broadening the inclusion criteria
can reduce the number of false negatives, at the price of possibly
increasing the number of false positives. When a gold standard is
not accessible to estimate the exact amount of false positives and
false negatives associated with the chosen algorithms, a systematic
approach to analyse them has the potential to support an approx-
imate estimation of validity.ollaerts et al., Quantifying outco
g/10.1016/j.vaccine.2019.07.04In an attempt to develop such a systematic approach, the com-
ponent algorithm strategy was introduced and tested [9]: such
strategy builds on the design a set of standardized algorithms for
the same event, called components, are defined and applied in each
database. The impact of different algorithms on the resulting esti-
mates of disease occurrence is subsequently measured and com-
pared across sites [9], thus providing qualitative evidence on the
amount of false positives and false negatives associated with each
algorithm. In this study we aimed to refine this strategy, by further
standardizing the process, by using benchmark data from an exter-
nal reference and by developing and applying novel formulae to
turn the observed differences into approximate estimates of valid-
ity. Since the proof-of-concept studies of ADVANCE focused on per-
tussis, we used this event as case study.2. Methods
2.1. Bordetella pertussis disease information
Bordetella pertussis causes pertussis, a vaccine-preventable
infectious disease of the respiratory tract. Symptoms include
paroxysms of cough typically lasting from 1 to 6 weeks or more
and these may be milder in adolescents or immunised children
[10,11]. Several tests are available to confirm Bordetella pertussis
infection, including culture (which takes up to 14 days), serology
and nucleic acid amplification tests. Pertussis is a notifiable infec-
tious disease and cases should be reported to the national surveil-
lance system in all the countries involved in ADVANCE. European
Union member states are required to report available data on per-
tussis cases to the European Centre for Disease Prevention and
Control (ECDC). A standardised case definition is used which clas-
sifies cases based on clinical, epidemiological and laboratory crite-
ria [12]. All national reports are submitted to the European
Surveillance System database (TESSy) managed by the ECDC [13].2.2. Data sources
We assessed the impact of different event-finding algorithms
using five databases that participated in the ADVANCE proof-of-
concept studies: BIFAP and SIDIAP (Spain), PEDIANET (Italy) and
RCGP RSC and THIN (United Kingdom). All databases were
population-based with data from electronic medical records in
the PC setting. In SIDIAP, the analyses were restricted to the popu-
lation in this PC database that could be linked to hospital discharge
records. Surveillance data on pertussis were obtained from the
TESSy surveillance system through ECDC, a partner of ADVANCE.me misclassification in multi-database studies: The case study of pertussis
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We used a dynamic cohort study design to study the impact of
different event-finding algorithms on the estimated pertussis IRs.
Due to the methodological nature of this study, to enable us to
explore in more detail a number of strategies, we included a larger
cohort in the study population than that in the other ADVANCE
studies. Therefore, children aged 0 to 14 years who were registered
in the participating databases entered the study cohorts on 1st Jan-
uary 2012 and 1st January 2014, and were followed up during 2012
and 2014, respectively. Children who were born during 2012 or
2014 were followed up from birth until the end of the calendar
year. Children who were older than 14 years at any point in the
follow-up were excluded. To exclude any previous cases that had
been notified before the start of the study period, children who
had a record of one of the components of pertussis during the
two years prior to one of the cohort entry dates were excluded,
unless the component referred to the data domain of drugs (see
below for more details on the component definition).
2.4. Selection of component algorithms
A component algorithm is a standardised event-finding algo-
rithm specified by three characteristics: the setting of primary data
collection (PC or hospital), the data domain (diagnosis, drugs, or
laboratory tests) involved in the algorithm, and the set of concepts
used to find the codes used to query the database [9]. In order to
create the sets of concepts we built on the process described else-
where: an initial list was created from the pertussis clinical defini-
tion, completed with a literature review [2,13] and was discussed
with local experts, who in some cases included free text strings
that were deemed to be pertinent; the process was supported by
the tool CodeMapper [14]. Labelling and classification of identified
concepts, as well as the construction of the components, were con-
ducted by one of the authors who is a pertussis expert (NvdM). As a
result, seven concept sets were created (Table 1) [15,16]. In partic-
ular, two sets of concepts belonged to the diagnoses data domain:Table 1
Sets of concepts selected for the component algorithms. Each set of concepts has a descr
available, a Concept Unique Identifier (CUI) of the Unified Medical Language System.
Concept set label Concept set description
(Bordetella pertussis) Concepts referring to diagnoses specifically
pertussis induced by an infection of Bordete
(Pertussis unspecified) Concepts referring to diagnoses which refer
but without a specific indication that Bordet
is responsible for the infection
(Symptoms compatible with pertussis) This set of concepts was introduced because
translation of ‘whooping cough’ was found
considered by physicians as a symptom, no
diagnosis
(Symptoms in infants) Concepts referring to symptoms that were
predictive of pertussis in infants [13,14]
(Macrolides) Use of macrolides
(Bordetella pertussis test) The concepts listed in this set indicate the
of tests that are considered to be confirmat
Bordetella pertussis infection
(Positive result from a Bordetella pertussis
test)
The concepts listed in this set indicate a po
from a tests confirmatory of a Bordetella pe
infection
Please cite this article as: R. Gini, C. N. Dodd, K. Bollaerts et al., Quantifying outco
in the ADVANCE project, Vaccine, https://doi.org/10.1016/j.vaccine.2019.07.04the set labelled ‘(Bordetella pertussis)’ included three concepts
which specifically indicated Bordetella pertussis as the causative
agent of the infection, while the set labelled ‘(pertussis unspeci-
fied)’ included five concepts indicating unspecified pertussis. The
corresponding codes and free text keywords are given in Supple-
mentary Table 1.
The primary components associating concepts with settings (PC
and hospital) are described in Table 2. Some secondary compo-
nents, combining primary components in pre-defined temporal
relations (e.g., symptoms in the presence of a drug prescription
in the previous 30 days) were also created.
2.5. Analysis
Each database manager received an R-coded programme (qual-
ity checked by double-coding against Stata) which was pro-
grammed using the pre-specified common data model [1]. These
programmes produced aggregated outputs, which were then trans-
ferred to the remote research environment. Event-finding algo-
rithms were created as logical combinations of individual
components using Boolean operators OR and AND: the combina-
tion of two components with the ‘OR’ operator allows to select
those subjects who are positive for either components; the combi-
nation of two components with the ‘AND’ operator allows to select
those subjects who are positive for both components. For example,
the two components ‘PC diagnosis, specific’ and ‘PC diagnosis,
unspecified’ were combined in one component: ‘PC specific OR
unspecified diagnoses’, which detected all individuals that had
any PC diagnosis, regardless of specificity. Based on the different
event-finding algorithms, incidence rates (IRs) were estimated
using the number of persons retrieved with the respective events
as numerator and the follow-up person-time as denominator (see
Supplementary File 1). Exact Poisson confidence intervals (95%
CI) were calculated [18].
Age and country-specific incidences per 100,000 person-years
of confirmed Bordetella Pertussis cases notified to the TESSy surveil-
lance system in both 2012 and 2014 were calculated for childreniption and can contain one or more concepts. Each concept has a description and, if
Concept CUI
mentioning
lla pertussis
Bordetella pertussis C0043167
Whooping cough due to Bordetella pertussis without
pneumonia
C2887068
Whooping cough due to Bordetella pertussis with
pneumonia
C2887069
to pertussis,
ella pertussis
Whooping cough due to unspecified organism C0043168
Bordetella infections C0006015
Whooping cough-like syndrome C0343485
Notification of whooping cough
Pneumonia in pertussis C0155865
the Spanish
to be
t as a
Concept of ‘tos pertusoide’ in Spanish general practice
found to be Apnea C0003578
Cyanosis C0010520
Post-tussive vomiting C1740793
Paroxysms of coughing C0231911
Macrolides
prescription
ory of a
Polymerase chain reaction test
Culture or serology
Isolation of Bordetella pertussis from a clinical specimen
sitive result
rtussis
Positive polymerase chain reaction test
Positive culture or serology
Positive isolation of Bordetella pertussis from a clinical
specimen
me misclassification in multi-database studies: The case study of pertussis
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Table 2
Components for pertussis. The concept sets referred to by the words in round parentheses can be found in Table 1.
Name Setting Data domain Concept set
PC diagnosis, specific Primary care practice Diagnosis (Bordetella pertussis)
Inpatient diagnosis, specific Hospital Diagnosis (Bordetella pertussis)
PC diagnosis, unspecified Primary care practice Diagnosis (Pertussis unspecified)
Inpatient diagnosis, unspecified Hospital Diagnosis (Pertussis unspecified)
Symptoms Primary care practice Diagnosis or signs/
symptoms
(Symptoms compatible with pertussis)
Symptoms in infants Primary care practice Diagnosis or signs/
symptoms
(Symptoms in infants)
Lab test Any setting where a laboratory test can be prescribed, or
facility where the test is administered
Laboratory test (Bordetella pertussis test)
Positive laboratory results Any setting where a health professional records the
results of a laboratory test, or facility where the results
of the test are generated
Results from laboratory
test
(Positive result from a Bordetella pertussis
test)
Drug use Facility dispensing medications or primary care practice
issuing prescriptions
Drug (Macrolides)
Secondary components
Symptoms and drugs within 30 days A patient is positive if they have both a record of symptoms and of drug use, and the interval between the dates is less than
30 days
Symptoms in infants and drugs within
30 days
A patient is positive if they are 0 or 1 and has both a record of symptoms in infants and of drug use, and the interval between
the dates is less than 30 days
4 R. Gini et al. / Vaccine xxx (xxxx) xxxaged 0–14 years. The calculations used the reported confirmed
cases in the TESSy surveillance system in 2012 and 2014 as the
numerator, and person-time from population distributions in
EUROSTAT for 2012 and 2014 as the denominator [17]. Exact Pois-
son confidence intervals (95% CI) were calculated [18].
Some formulae link the true proportion of BorPer and/or valid-
ity indices with each other and with the observed proportion of the
component algorithms (Table 3). These formulas are explained in
Supplementary File 2.
In this study we considered P = IR (see Supplementary File 1)
and we assumed that for all algorithms A and B, the proportion
of true positives among those detected by both algorithms (PPV
of A AND B), was the same as the PPV of A or of B, whichever
was the highest: this may be considered the most conservative
assumption, since being retrieved by two algorithms is at least as
reliable a criterion as the better of the two.
We expected that the component ‘PC diagnosis, specific’ would
not be not sensitive enough to retrieve all the cases of Bordetella
pertussis occurred in the database study population, but that the
composed algorithm ‘PC specific OR unspecified diagnoses’ would
retrieve, alongside with some true cases, also some false positives.
Moreover we were aware that some cases diagnosed and treated in
hospital rather than in PC, would not be retrieved by ‘PC specific
OR unspecified diagnoses’, either. We therefore aimed to use the
formulae in Table 3 to provide an approximate estimation of the
amount of false positives and false negatives of the algorithm ‘PC
specific OR unspecified diagnoses’. To this aim, we used SIDIAP,
because it was the only database where we could observe casesTable 3
Analytic formulae linking the true proportion of pertussis and
P is the true proportion of cases of pertussis, P is the proportio
and PPV is the positive predictive value of the algorithm.
Known parameters
One algorithm
PPV and SE
PPV and P
SE and P
Two algorithms A and B
SE of A, of B, and of A AND B
P and PPV of A, of B, and of A AND B
SE of A OR B, and PPV of A, of B, and of A AND B
PPV of A, of B, and of A AND B
Please cite this article as: R. Gini, C. N. Dodd, K. Bollaerts et al., Quantifying outco
in the ADVANCE project, Vaccine, https://doi.org/10.1016/j.vaccine.2019.07.04retrieved in hospital but not in PC. In order to apply our formulae
we had to make assumptions on three parameters: (a) the PPV of
the components associated with the ‘(Bordetella pertussis)’ concept
set: since this is composed of codes explicitly mentioning the bac-
terium, we considered that its associated components had a high
likelihood of extracting true cases; we chose 90% as a conservative
assumption for this PPV; (b) the PPV of the components associated
with the ‘(pertussis unspecified)’ concept set: we explored two sce-
narios, i.e. 70% or 50%; and (c) the sensitivity of the composite of
the four diagnosis and laboratory components: we assumed that
all true cases in SIDIAP were recorded in at least one of the diagno-
sis or laboratory-based components. Note that, based on our clini-
cal definition of true case the component ‘positive laboratory
results’ only retrieves true cases, hence its PPV is 100%.
Based on the approximated sensitivity and PPV estimates for
the algorithm ‘PC specific OR unspecified diagnosis’ in SIDIAP we
computed the adjusted IR of BorPer in the relevant study
population.
3. Results
3.1. Study population
We followed 3,173,268 person-years of children during the
study period: 488,847 from the SIDIAP database, 796,324 from
BIFAP, 88,754 from PEDIANET, 1,387,939 from THIN and 411,404
from RCGP RSC (Table 4). The percentages of children aged 0 or
1 years in the population aged 0–14 years in Spain were 12.1%validity indices of one or two algorithms. In the formulas,
n of cases detected by the algorithm, SE is the sensitivity
Formula to derive another parameter
p ¼ PPPVSE
SE ¼ PPPVp
PPV ¼ SEpP
SEAORB ¼ SEA þ SEB  SEAANDB
SEAORB ¼ PAPPVAp þ PBPPVBp  PAANDBPPVAANDBp
p ¼ PAPPVAþPBPPVBPAANDBPPVAANDBSEAORB
PPVAANDB ¼ PAPPVAþPBPPVBPAANDBPPVAANDBPPVAORB
me misclassification in multi-database studies: The case study of pertussis
5
Ta
bl
e
4
St
ud
y
re
su
lt
s.
N
um
be
r
of
pe
rs
on
-y
ea
rs
(P
Ys
)
en
te
ri
ng
th
e
st
ud
y
in
ea
ch
da
ta
ba
se
.I
nc
id
en
ce
ra
te
s
of
pe
rt
us
si
s
pe
r
10
0,
00
0
ch
ild
re
n
ag
ed
0–
14
,w
it
h
95
%
co
nfi
de
nc
e
in
te
rv
al
(C
I)
,f
ro
m
th
e
TE
SS
y
su
rv
ei
lla
nc
e
sy
st
em
in
th
e
co
rr
es
po
nd
in
g
co
un
tr
y
an
d
th
e
es
ti
m
at
e
in
ci
de
nc
e
ra
te
pe
r
10
0,
00
0
fo
r
ea
ch
co
m
po
ne
nt
al
go
ri
th
m
ar
e
sh
ow
n.
In
co
m
po
si
te
al
go
ri
th
m
s,
th
e
in
ci
de
nc
e
ra
te
s
w
er
e
st
ra
ti
fi
ed
pe
r
ty
pe
of
ca
se
:
ca
se
s
de
te
ct
ed
on
ly
by
th
e
le
ft
-h
an
d
co
m
po
ne
nt
(i
nd
ic
at
ed
in
th
e
la
be
l
be
fo
re
th
e
ke
yw
or
d
’O
R’
),
ca
se
s
de
te
ct
ed
by
bo
th
co
m
po
ne
nt
s,
an
d
ca
se
s
de
te
ct
ed
by
th
e
ri
gh
t-
ha
nd
co
m
po
ne
nt
(i
nd
ic
at
ed
in
th
e
la
be
l
af
te
r
th
e
ke
yw
or
d
’O
R’
).
D
at
a
fo
r
ye
ar
s
20
12
an
d
20
14
w
er
e
po
ol
ed
.
D
B
SI
D
IA
P
(S
pa
in
)
B
IF
A
P
(S
pa
in
)
PE
D
IA
N
ET
(I
ta
ly
)
TH
IN
(U
n
it
ed
K
in
gd
om
)
R
C
G
P
(U
n
it
ed
K
in
gd
om
)
Pe
rs
on
-y
ea
rs
48
8,
84
7
79
6,
32
4
88
,7
54
1,
38
7,
93
9
41
1,
40
4
TE
SS
y
(I
R
an
d
95
%
C
I)
21
.2
(2
0.
5–
22
.0
)
21
.2
(2
0.
5–
22
.0
)
5.
4
(5
.1
–5
.8
)
13
.4
(1
3.
0–
13
.9
)
13
.4
(1
3.
0–
13
.9
)
C
om
po
n
en
t
al
go
ri
th
m
s
(N
an
d
IR
pe
r
10
0,
00
0
PY
s)
PC
di
ag
n
os
is
,s
pe
ci
fi
c
21
(4
.3
)
0
(0
.0
)
2
(2
.3
)
79
(5
.7
)
21
(5
.1
)
PC
di
ag
n
os
is
,u
n
sp
ec
ifi
ed
17
3
(3
5.
4)
13
5
(1
7.
0)
37
(4
1.
7)
17
8
(1
2.
8)
77
(1
8.
7)
In
pa
ti
en
t
di
ag
n
os
is
,s
pe
ci
fi
c
27
(5
.5
)
In
pa
ti
en
t
di
ag
n
os
is
,u
n
sp
ec
ifi
ed
26
(5
.3
)
Sy
m
pt
om
s
16
6
(2
0.
8)
Sy
m
pt
om
s
an
d
dr
u
g
w
it
h
in
30
da
ys
12
2
(1
5.
3)
Sy
m
pt
om
s
in
in
fa
n
ts
27
(5
.5
)
6
(6
.8
)
17
2
(1
2.
4)
30
(7
.3
)
Sy
m
pt
om
s
in
in
fa
n
ts
an
d
dr
u
g
w
it
h
in
30
da
ys
1
(0
.2
)
8
(0
.6
)
La
b
te
st
96
(1
9.
6)
38
(4
.8
)
38
(4
2.
8)
20
9
(1
5.
1)
32
(7
.8
)
Po
si
ti
ve
la
bo
ra
to
ry
re
su
lt
s
19
(3
.9
)
0
(0
.0
)
3
(0
.2
)
C
om
po
si
te
al
go
ri
th
m
s
N
(I
R
)
N
(I
R
)
in
le
ft
-h
an
d
co
m
po
n
en
t
on
ly
N
(I
R
)
In
bo
th
co
m
po
n
et
s
N
(I
R
)
In
ri
gh
t-
h
an
d
co
m
po
n
en
t
on
ly
N
(I
R
)
N
(I
R
)
in
le
ft
-h
an
d
co
m
po
n
en
t
on
ly
N
(I
R
)
In
bo
th
co
m
po
n
et
s
N
(I
R
)
In
ri
gh
t-
h
an
d
co
m
po
n
en
t
on
ly
N
(I
R
)
N
(I
R
)
in
le
ft
-h
an
d
co
m
po
n
en
t
on
ly
N
(I
R
)
In
bo
th
co
m
po
n
et
s
N
(I
R
)
In
ri
gh
t-
h
an
d
co
m
po
n
en
t
on
ly
N
(I
R
)
N
(I
R
)
in
le
ft
-h
an
d
co
m
po
n
en
t
on
ly
N
(I
R
)
In
bo
th
co
m
po
n
et
s
N
(I
R
)
In
ri
gh
t-
h
an
d
co
m
po
n
en
t
on
ly
N
(I
R
)
N
(I
R
)
in
le
ft
-h
an
d
co
m
po
n
en
t
on
ly
N
(I
R
)
In
bo
th
co
m
po
n
et
s
N
(I
R
)
In
ri
gh
t-
h
an
d
co
m
po
n
en
t
on
ly
PC
sp
ec
ifi
c
O
R
u
n
sp
ec
ifi
ed
di
ag
n
os
is
19
4
(3
9.
6)
21
(4
.3
)
0
(0
.0
)
17
3
(3
5.
4)
13
5
(1
7.
0)
0
(0
.0
)
0
(0
.0
)
13
5
(1
7.
0)
39
(4
3.
9)
2
(2
.2
)
0
(0
.0
)
37
(4
1.
7)
24
6
(1
7.
7)
68
(4
.9
)
11
(0
.8
)
16
7
(1
2.
0)
91
(2
2.
1)
14
(3
.4
)
7
(1
.7
)
70
(1
7.
0)
In
pa
ti
en
t
sp
ec
ifi
c
O
R
u
n
sp
ec
ifi
ed
di
ag
n
os
is
52
(1
0.
6)
25
(5
.1
)
1
(0
.2
)
26
(5
.3
)
PC
O
R
in
pa
ti
en
t
di
ag
n
os
is
22
0
(4
5.
0)
16
8
(3
4.
3)
26
(5
.3
)
26
(5
.3
)
PC
di
ag
n
os
is
O
R
la
b
te
st
27
1
(5
5.
4)
77
(1
5.
8)
19
(3
.9
)
17
5
(3
5.
8)
16
8
(2
1.
1)
33
(4
.1
)
5
(0
.6
)
13
0
(1
6.
3)
69
(7
7.
7)
30
(3
3.
8)
8
(9
.0
)
31
(3
4.
9)
42
6
(3
0.
7)
18
1
(1
3.
0)
29
(2
.1
)
21
7
(1
5.
6)
11
5
(2
8.
0)
24
(5
.8
)
8
(1
.9
)
83
(2
0.
2)
Po
si
ti
ve
la
b
re
su
lt
s
O
R
PC
di
ag
n
os
is
19
7
(4
0.
3)
3
(0
.6
)
16
(3
.3
)
17
8
(3
6.
4)
13
5
(1
7.
0)
0
(0
.0
)
0
(0
.0
)
13
5
(1
7.
0)
24
7
(1
7.
8)
1
(0
.1
)
2
(0
.1
)
24
4
(1
7.
6)
PC
di
ag
n
os
is
O
R
sy
m
pt
om
s
an
d
dr
u
gs
25
5
(3
2.
0)
13
3
(1
6.
7)
2
(0
.3
)
12
0
(1
5.
1)
A
n
y
di
ag
n
os
is
O
R
po
si
ti
ve
la
b
re
su
lt
s
22
3
(4
5.
6)
20
4
(4
1.
7)
16
(3
.3
)
3
(0
.6
)
R. Gini et al. / Vaccine xxx (xxxx) xxx 5
Please cite this article as: R. Gini, C. N. Dodd, K. Bollaerts et al., Quantifying outco
in the ADVANCE project, Vaccine, https://doi.org/10.1016/j.vaccine.2019.07.04and 16.1% in SIDIAP in BIFAP, respectively, compared with 13.5% in
the EUROSTAT Spanish population. In the UK the percentages were
15.1% and 14.8% in RCGP RSC and THIN 13.0%, respectively, com-
pared with 14.3% in the EUROSTAT UK population. The percentage
was 13.0% in PEDIANET, compared with 12.9% in the EUROSTAT
Italian population.
3.2. Incidence rates estimated by the algorithms
The IRs for the component and composite algorithms, as well as
the benchmark IRs from the TESSy surveillance system are illus-
trated in Fig. 1 and documented in Table 4, while 95% confidence
intervals are included in Supplementary Table 2. The IRs estimated
from the TESSy surveillance system in 2012 and 2014 for children
aged 0–14 years were 21.2 (95% CI: 20.5; 22.0) for Spain, 13.4 (95%
CI: 13.0; 13.9) for the United Kingdom, and 5.4 (95% CI: 5.1; 0.8) for
Italy. The number of cases of ‘PC diagnosis, specific’ (and IRs per
100,000 PY) were 0 (IR = 0.0), 21 (IR = 4.3), 21 (IR = 5.1), 79
(IR = 5.7), and 2 (IR = 2.3) in the BIFAP, SIDIAP, RCGP RSC, THIN
and PEDIANET databases, respectively. The component ‘PC diagno-
sis, unspecified’ had a higher IR in all databases, and combining the
two components (‘PC specific OR unspecified diagnosis’) increased
the number of cases detected and the IRs to 135 (IR = 17.0), 194
(IR = 39.6), 39 (IR = 43.9), 246 (IR = 17.7), and 91 (IR = 22.1), respec-
tively. In BIFAP, SIDIAP, RCGP RSC and THIN, the IRs were similar or
higher with respect to the corresponding IRs from the TESSy
surveillance system (17.0 vs 21.2; 39.6 vs. 21.2; 22.1 vs. 13.4;
17.7 vs. 13.4, respectively): this is consistent with the expectation
that the unspecified component captured, alongside with some
true cases, also some false positives. In PEDIANET the composite
IR was also higher than the IR from the TESSy database, but unlike
in the other databases, where the IR was less than double, in
PEDIANET a disproportionate difference was observed (43.9 vs 5.4).
SIDIAP was the only database in which data from both the PC
and hospital settings could be linked. The total number of cases
in ‘PC OR inpatient diagnosis’ in SIDIAP was 220 (IR = 45.0), includ-
ing 26 (12%) that had not been identified in the PC setting. Unlike
in the PC setting, where most of the diagnoses were unspecified, in
the inpatient setting there were around half specific and half
unspecified diagnoses.
In BIFAP, the ‘symptoms and drugs within 30 days’ component
identified 122 cases with an IR of 15.3 per 100,000 PYs. When this
component was combined with ‘PC specific OR unspecified diagno-
sis’, the IR increased to 32.0, which was higher than the reference
IR which was 21.2. Almost none of the children aged 0 or 1 year old
in ‘symptoms in infants’ in any database had a corresponding pre-
scription or dispensing of macrolides in the ‘symptoms in infants
and drugs within 30 days’ component.
The ‘lab test’ component was available in all databases and had
a relatively high IR (from 4.8 in BIFAP to 42.8 in PEDIANET). ‘Posi-
tive laboratory results’ were only available in SIDIAP and THIN,
with only 19 and 3 cases, respectively. In SIDIAP, 3 of the 19 cases
were not captured by a diagnosis in either primary care or hospital
settings.
In Supplementary Fig. 1 and Supplementary Table 3, the analy-
sis was repeated for infants (children aged 0 or 1). The IRs in this
subpopulation were around three times higher than the IRs in
the overall study population. The findings confirmed the relation-
ship between components observed in the general study popula-
tion, with the exception of ‘PC OR inpatient diagnosis’ in SIDIAP
(n = 98), where 25.5% (n = 25) were not retrieved from the PC set-
ting, vs 11.8% in the overall study population.
In order to obtain an approximate estimate of algorithm valid-
ity, we explored two scenarios in SIDIAP, corresponding to differ-
ent assumptions for PPV of ‘PC diagnosis, unspecified’ and of
‘inpatient diagnosis, unspecified’: in the first scenario, PPV wasme misclassification in multi-database studies: The case study of pertussis
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Any diagnosis OR positive lab results
PC diagnosis OR symptoms and drugs
Positive lab results OR PC diagnosis
PC diagnosis OR lab test
PC OR inpatient diagnosis
Inpatient specific OR unspecified diagnosis
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Laboratory results
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Symptoms in infants and drug within 30days
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Left-hand side component only Both components Right-hand side component only
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Incidence rate (per 100,000 person-years)
Fig. 1. Study results for the incidence of tested component and composite algorithms. For each component algorithm the incidence rate per 100,000 person-years is shown.
For the composite algorithms, the incidence rates were stratified per type of case: the gray bar represents cases detected only by the left-hand component (indicated in the
label before the key Boolean operator ‘OR’); the black bar represents cases detected by both components; the white bar represents cases detected by the right-hand
component (indicated in the label after the key Boolean operator word ‘OR’). The dashed line represents the national incidence rate per 100,000 person-years based on data
from the TESSy surveillance system. Data for years 2012 and 2014 were pooled.
6 R. Gini et al. / Vaccine xxx (xxxx) xxx70%, in the second scenario, PPV was 50%. As a consequence, in the
first scenario ‘PC specific OR unspecified diagnosis’ had a PPV of
72% (or, in the second scenario: 54%) and a sensitivity of 85% (or,
in the second scenario: 83%). Based on this estimate, the adjusted
IR of BorPer in the SIDIAP study population was 35.5 per 100,000
PY (or, in the second scenario: 25.9) vs the TESSy surveillance sys-
tem IR 21.2.4. Discussion
We designed and applied several algorithms as potential strate-
gies to detect cases of Bordetella pertussis and thus estimate the IR
in five European healthcare databases. The IRs estimated by these
algorithms were heterogeneous within and between databases.
The algorithm retrieving specific Bordetella pertussis diagnostic
codes from the PC setting was consistently underestimating IR
with respect to the reference estimates from TESSy surveillance
system. More sensitive algorithms mostly retrieved a higher num-
ber of cases than then number predicted by the TESSy surveillance
system, which is compatible with the retrieval of some false posi-
tives. Among all the algorithms tested, the one retrieving either
specific Bordetella pertussis or unspecified pertussis diagnostic
codes from the PC setting, despite including probably some false
positives, still was not perfectly sensitive, as it was probably miss-
ing some of the cases diagnosed and treated in hospital setting. In
SIDIAP, in which both hospital and PC diagnoses are collected and
can be linked when they refer to the same patient, this expectation
was confirmed, since hospital cases were found to be partially
missing in PC. In fact, based on a few assumptions and some novel
formulae, we could obtain, in SIDIAP, a range of approximate esti-
mates of PPV and sensitivity of this algorithm from the observed
IRs: PPV ranged from 54% to 72% and from 83% to 85%, respectively.
Based on such approximate values of PPV and sensitivity, the esti-
mate of adjusted IRs of Bordetella pertussis in the corresponding
population ranged from 25.9 to 35.5 per 100,000 person-years,
against the TESSy surveillance system estimate of 21.2.4.1. General comments
Three components were expected to have a high PPV: PC and
inpatient specific diagnoses, and positive laboratory results. Two
were expected to have lower PPV (PC and inpatient unspecifiedPlease cite this article as: R. Gini, C. N. Dodd, K. Bollaerts et al., Quantifying outco
in the ADVANCE project, Vaccine, https://doi.org/10.1016/j.vaccine.2019.07.04diagnoses). One was expected to be sensitive (prescription of a lab-
oratory test), two were very unspecific (symptoms and symptoms
in infants) and were planned to be used only in combination with
the last component (prescription or use of macrolides) in a 30-days
window of time.
In all the databases, the combination of the components which
was expected to have a high PPV (specific diagnoses and laboratory
tests) identified less cases than the number expected from the
TESSy surveillance system,. We concluded that some of the cases
recorded with an unspecified diagnosis were actually true Borde-
tella pertussis cases, that had not been updated when the diagnosis
was confirmed. One possible explanation could be that it takes sev-
eral days to confirm the diagnosis of pertussis after the disease is
suspected, and there may be no opportunity for the specific diag-
nosis to be recorded if the patient does not return to the healthcare
facility. Another possible explanation may be that the medical per-
sonnel may not see the need to update the record for the purposes
of clinical care, or that they rather prefer recording informal terms
in the event of sharing their records with the patients themselves.
This attitude may be influenced by the level of awareness of possi-
ble reuse of electronic records for research purposes. These poten-
tial explanations may have varying levels of impact in the different
databases. For example, in some databases we observed that
among the cases detected by a diagnostic component (unspecified
or specific), the specific diagnosis was more frequent.
Based on the results of this study, in all the databases it is now
possible to design sensitivity analysis using a more specific (but
less sensitive) definition of pertussis. In case of heterogeneity the
results of a study concerning pertussis, either as an outcome or a
study cohort characteristic, designing such sensitivity analyses
should be considered as a valid option. On the other hand, in all
the databases there is now a possible choice among with different
sensitivity: we explored several of them, among which ‘unspecified
diagnoses’ (the most conservative) and ‘test’ (the least conserva-
tive). Even though these algorithms are likely to have lower PPVs,
they may still be useful for sensitivity analyses, especially if there
are reasons to think that a specific algorithm could be affected by
differential misclassification. For example, pertussis may be more
readily suspected and tested for in unvaccinated children, and
therefore would be recorded in a more accurate manner. In the
event that validation with a gold standard is available, validating
cases selected via a sensitive algorithm has the chance to identify
cases that were not recorded with a diagnostic code.me misclassification in multi-database studies: The case study of pertussis
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be sensitive and, although it was likely to have a low PPV, it was
less prone to differential misclassification, because it captured
symptoms that physicians may not think of as being related with
pertussis. However this component proved to be unusable; in real-
ity, when we added a secondary component for concurrent macro-
lide use there were very few cases that would have been expected
to be found in infants with an infection. In contrast, we developed a
component specifically for the symptom ’pertussis-like cough’ (tos
pertusoide in Spanish language) that was apparently specific for
pertussis cases that were only found in the BIFAP database. Not
only did the majority of cases have a concurrent record of prescrip-
tion of macrolides, but a manual review of a sample of 100 records
including physician free text comments, found 2 cases of unspeci-
fied pertussis and 2 cases of suspected pertussis. Therefore, this
component may be considered for sensitivity analysis or as source
for cases to be validated.
4.2. Compatibility with TESSy and seroprevalence surveys
In this study we were able to compare the IRs estimated for pae-
diatric cohorts in five databases using the various algorithms with
the national IR estimates from ECDC’s TESSy surveillance database.
The cases captured by the two types of systems were expected to
be slightly different, for various reasons. First, TESSy provides esti-
mates at the national level using census denominators, while three
of the databases participating in this study had a regional/multire-
gional scope (SIDIAP, BIFAP and PEDIANET) and two were based on
a representative sample of the national population (THIN, RCGP
RSC). Therefore it is possible that some clusters of the infectious
disease might be under or over-represented in these database. Sec-
ond, we collected only confirmed cases from TESSy, while some
true cases captured by a PC database with a sensitive algorithm
may never be confirmed (under ascertainment), or may never be
notified (underreporting) [19,20]. Thus the databases may be a
complementary source of true cases which are not notified, while
adding potentially false positive cases. Finally, the TESSy data for
pertussis may also be affected by under ascertainment and
underreporting.
The IR found for PEDIANET, which was much higher than the IR
estimate from TESSy for Italy (43.9 vs 5.4), may be explained by a
combination of both phenomena discussed above. PEDIANET col-
lects data from PC physicians working in the Italian region Veneto,
in the North East of the country. The Regional Office for Infectious
Diseases of the Veneto Region provided an estimated IR of 10.0 to
the data custodians of PEDIANET. This shows that the region had a
higher pertussis notification rate than at the national level for 2012
and 2014, although almost all the diagnoses in PEDIANET were
unspecified. However, the regional estimate could be underesti-
mated because of under ascertainment. Finally, as in the other
databases, many cases in PEDIANET could be false positives. In gen-
eral, if estimates of the PPV of the diagnoses are available, the esti-
mated IR from databases can provide a quantitative estimate of
under ascertainment and under notification in TESSy. Vice versa,
if under notification to TESSy is known to be small, estimates of
the PPV for the algorithm can be obtained.
In SIDIAP we assumed a range of plausible values for PPV of
unspecified diagnoses (50 and 70%) and that PPV of specific diag-
noses was 90%. Under those assumptions the adjusted IR of Borde-
tella pertussis in the database study population was higher than the
IR from TESSy. This suggests either that the assumptions we made
on PPVs were too generous, or that the number of cases predicted
by the TESSy rates was lower than the number truly occurred in
the database study population.
Results from seroprevalence surveys have provided estimates
for the incidence of Bordetella pertussis infection [21–23]. ThesePlease cite this article as: R. Gini, C. N. Dodd, K. Bollaerts et al., Quantifying outco
in the ADVANCE project, Vaccine, https://doi.org/10.1016/j.vaccine.2019.07.04have provided prevalence estimates beyond those of the surveil-
lance systems, partly as they also capture asymptomatic or mildly
symptomatic infections. On the contrary, in this study, we
observed that estimates of incidence obtained from databases are
roughly comparable with those of TESSy.4.3. Scope of the component strategy
The scope of this component strategy goes beyond ADVANCE
and has the potential of being a comprehensive tool to address
heterogeneity and disease misclassification in databases, particu-
larly in multi-database pharmacoepidemiology studies. Compo-
nents should be designed by individuals who have expertise in
the databases involved, and can be used to approach their hetero-
geneous characteristics in a standardized, transparent and system-
atic fashion.
Inspection of components can provide knowledge that can
inform the design of validation studies: for instance, cases to be
validated could be chosen among those positive for a component
with high sensitivity and low PPV, such as the component ‘lab test’
in our study. In many European databases, estimating the PPV of
simple algorithms such as components is feasible in a relatively
timely and inexpensive way [24–26]. If this is not feasible, scenar-
ios for possible PPVs of the components can be exhibited, based on
their characteristics: for instance in our case, some components
were expected to have higher sensitivity and lower PPVs. Regard-
less of their source (validation, external sources or assumptions)
the PPVs of components can finally be incorporated in our formulas
in Table 3 and provide a picture of the overall validity.
Finally, comparing the distribution of components across expo-
sure strata can indicate if differential misclassification is to be sus-
pected. Differential misclassification can be an important source of
bias, even if validity is high [5, 6, [27,28]. If components are
unevenly distributed across exposure strata, sensitivity analyses
of the study results must be conducted to check whether they
are robust to differential misclassification, and components with
different validity can be used to this aim.4.4. Strengths and limitations
In this study, we used standardised component algorithms as a
transparent way of documenting the data extraction process across
multiple databases. At the same time, we could also perform a
qualitative evaluation of the expected validity of each component
of Bordetella pertussis, based on its specified semantics and set-
ting. Quantitative scenarios for the validity of each component
can also be made using the same approach. We showed that esti-
mates of the validity of various composite algorithms can then
be derived in a purely algebraic manner. We could use the inci-
dence estimates based on data from the TESSy surveillance system,
which is where European Union member states are required to
report pertussis cases, as a reference value, although we cannot
exclude the possibility that they may also be subject to under
ascertainment and underreporting.
The estimates of sensitivity that we obtained for SIDIAP cannot
be generalised to the other PC databases. The sensitivity of the PC
databases depends on how often a person with the disease symp-
toms would seek attention in a PC practice. Although in all the
databases, the PC physicians have a gatekeeper role, emergency
care can be sought without PC referral, and PC practices may not
be accessible at night or weekends. Referrals from other settings
may be recorded in the PC practice, but no automatic mechanism
is in place. In the absence of a database-specific estimate, however,
estimates from another database are a realistic alternative to the
assumption that sensitivity is 100%.me misclassification in multi-database studies: The case study of pertussis
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Retrieving BorPer cases using only specific concepts has low
sensitivity in PC databases, while including cases retrieved by
unspecified concepts introduces false positives, which were
approximately estimated to be 28% in one database. The share of
cases that cannot be retrieved from a PC database because they
are only seen in hospital was approximately estimated to be 15%
in one database. This study demonstrated that quantifying the
impact of different event-finding algorithms across databases and
benchmarking with disease surveillance data can provide approx-
imate estimates of algorithm validity.
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PHE: Public Health England (www.gov.uk/government/organi-
sations/public-health-england)
THL: National Institute for Health and Welfare (www.thl.fi)
UMCU: Universitair Medisch Centrum Utrecht (www.umcu.nl)
UOA: University of Athens (www.uoa.gr)
UNIME: University of Messina (www.unime.it)me misclassification in multi-database studies: The case study of pertussis
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R. Gini et al. / Vaccine xxx (xxxx) xxx 9Vaccine.Grid: Vaccine.Grid (http://www.vaccinegrid.org/)
VVKT: State Medicines Control Agency (www.vvkt.lt)
WUM: Polish Medicines Agency - Warszawski Uniwersytet
Medyczny (https://wld.wum.edu.pl/)
Appendix B. Supplementary material
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.vaccine.2019.07.045.
References
[1] Sturkenboom M, van der Aa L, Bollaerts K, Emborg HD, Ferreira G, Gini R, et al.
The ADVANCE distributed network system for evidence generation on vaccines
coverage, benefits and risks based on electronic health care data. Vaccine.
2018; Paper 2 in supplement.
[2] Sturkenboom M, Weibel D, van der Aa L, Braeye T, Gheorge M, Becker B, et al.
ADVANCE database characterization and fit for purpose assessment for multi-
country studies on the coverage, benefits and risks of vaccinations. Vaccine.
2018;Paper 3 in Supplement.
[3] Gini R, Schuemie M, Brown J, Ryan P, Vacchi E, Coppola M, et al. Data extraction
and management in networks of observational health care databases for
scientific research: a comparison of EU-ADR, OMOP, Mini-Sentinel and
MATRICE strategies. EGEMS (Washington, DC) 2016;4:1189.
[4] Avillach P, Coloma PM, Gini R, Schuemie M, Mougin F, Dufour JC, et al.
Harmonization process for the identification of medical events in eight
European healthcare databases: the experience from the EU-ADR project. J
Am Med Inform Assoc 2013;20:184–92.
[5] Funk MJ, Landi SN. Misclassification in administrative claims data: quantifying
the impact on treatment effect estimates. Curr Epidemiol Rep 2014;1:175–85.
[6] Hofler M. The effect of misclassification on the estimation of association: a
review. Int J Methods Psychiatr Res 2005;14:92–101.
[7] De Smedt T, Merrall E, Macina D, Perez-Vilar S, Andrews N, Bollaerts K. Bias
due to differential and non-differential disease- and exposure misclassification
in studies of vaccine effectiveness. PLoS One 2018;13:e0199180.
[8] Brenner H, Gefeller O. Use of the positive predictive value to correct for disease
misclassification in epidemiologic studies. Am J Epidemiol 1993;138:1007–15.
[9] Roberto G, Leal I, Sattar N, Loomis AK, Avillach P, Egger P, et al. Identifying
cases of type 2 diabetes in heterogeneous data sources: strategy from the EMIF
Project. PLoS One 2016;11:e0160648.
[10] Barlow RS, Reynolds LE, Cieslak PR, Sullivan AD. Vaccinated children and
adolescents with pertussis infections experience reduced illness severity and
duration, Oregon, 2010–2012. Clin Infect Dis 2014;58:1523–9.
[11] McNamara LA, Skoff T, Faulkner A, Miller L, Kudish K, Kenyon C, et al. Reduced
severity of pertussis in persons with age-appropriate pertussis vaccination-
United States, 2010–2012. Clin Infect Dis 2017;65:811–8.
[12] European Parliament and of the Council. (Decision EU 2012) Commission
implementing decision of 8 August 2012 amending Decision 2002/253/EC
laying down case definitions for reporting communicable diseases to the
Community network under Decision No 2119/98/EC of the European
Parliament and of the Council. Annex to L 262. Official Journal of the
European Union 27/9/2012. Available at: http://eur-lex.europa.eu/legal-
content/EN/TXT/PDF/?uri=CELEX:32012D0506&qid=1428573336660&from=
EN#page=22. [accessed on: 9 November 2018].Please cite this article as: R. Gini, C. N. Dodd, K. Bollaerts et al., Quantifying outco
in the ADVANCE project, Vaccine, https://doi.org/10.1016/j.vaccine.2019.07.04[13] European Centre for Disease Prevention and Control. The European
Surveillance System (TESSy). Available at: https://ecdc.europa.eu/en/
publications-data/european-surveillance-system-tessy. [accessed on: 9
November 2018].
[14] Becker BFH, Avillach P, Romio S, van Mulligen EM, Weibel D, Sturkenboom M,
et al. CodeMapper: semiautomatic coding of case definitions. A contribution
from the ADVANCE project. Pharmacoepidemiol Drug Saf 2017;26
(8):998–1005.
[15] Bellettini CV, de Oliveira AW, Tusset C, Baethgen LF, Amantea SL, Motta F, et al.
laboratorial and radiographic predictors of Bordetella pertussis infection].
Revista paulista de pediatria : orgao oficial da. Sociedade de Pediatria de Sao
Paulo. 2014;32:292–8.
[16] Hurtado-Mingo A, Mayoral-Cortes JM, Falcon-Neyra D, Merino-Diaz L,
Sanchez-Aguera M. Obando I [Clinical and epidemiological features of
pertussis among hospitalized infants in Seville during 2007–2011]. Enferm
Infecc Microbiol Clin 2013;31:437–41.
[17] Eurostat. Population data. Available at: https://ec.europa.eu/eurostat/web/
population-demography-migration-projections/population-data/database.
[accessed on: 12 November 2018].
[18] Ulm K. A simple method to calculate the confidence interval of a standardized
mortality ratio (SMR). Am J Epidemiol 1990;131:373–5.
[19] McDonald SA, Teunis P, van der Maas N, de Greeff S, de Melker H, Kretzschmar
ME. An evidence synthesis approach to estimating the incidence of
symptomatic pertussis infection in the Netherlands, 2005–2011. BMC Infect
Dis 2015;15:588.
[20] Schielke A, Takla A, von Kries R, Wichmann O, Hellenbrand W. Marked
underreporting of pertussis requiring hospitalization in infants as estimated
by capture-recapture methodology, Germany, 2013–2015. Pediatr Infect Dis J
2018;37:119–25.
[21] Barkoff AM, Grondahl-Yli-Hannuksela K, He Q. Seroprevalence studies of
pertussis: what have we learned from different immunized populations.
Pathog Dis 2015;73.
[22] de Greeff SC, de Melker HE, van Gageldonk PG, Schellekens JF, van der Klis FR,
Mollema L, et al. Seroprevalence of pertussis in The Netherlands: evidence for
increased circulation of Bordetella pertussis. PLoS One 2010;5:e14183.
[23] de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M. The
incidence of Bordetella pertussis infections estimated in the population from a
combination of serological surveys. J Infect 2006;53:106–13.
[24] Coloma PM, Valkhoff VE, Mazzaglia G, Nielsson MS, Pedersen L, Molokhia M,
et al. Identification of acute myocardial infarction from electronic healthcare
records using different disease coding systems: a validation study in three
European countries. BMJ Open 2013;3.
[25] Valkhoff VE, Coloma PM, Masclee GM, Gini R, Innocenti F, Lapi F, et al.
Validation study in four health-care databases: upper gastrointestinal
bleeding misclassification affects precision but not magnitude of drug-
related upper gastrointestinal bleeding risk. J Clin Epidemiol 2014;67:921–31.
[26] Gini R, Schuemie MJ, Mazzaglia G, Lapi F, Francesconi P, Pasqua A, et al.
Automatic identification of type 2 diabetes, hypertension, ischaemic heart
disease, heart failure and their levels of severity from Italian General
Practitioners’ electronic medical records: a validation study. BMJ Open
2016;6:e012413.
[27] De Smedt T, Merrall E, Macina D, Perez-Vilar S, Andrews N, Bollaerts K. Bias
due to differential and non-differential disease- and exposure misclassification
in studies of vaccine effectiveness. PLoS One 2018;13(6):e0199180.
[28] Newcomer SR, Kulldorff M, Xu S, Daley MF, Fireman B, Lewis E, et al. Bias from
outcome misclassification in immunization schedule safety research.
Pharmacoepidemiol Drug Saf 2018 Feb 1;27(2):221–8.me misclassification in multi-database studies: The case study of pertussis
5
